Abstract
208O Asian subgroup analysis of the THOR phase III study: Erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer and selected fibroblast growth factor receptor alterations
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have